BioMarin Pharmaceutical has dosed the first child in its Phase II trial of BMN 111, an analog of C-type Natriuretic Peptide (CNP), for the treatment of children with achondroplasia. Achondroplasia is the most common form of disproportionate short stature or dwarfism. The study is an open-label, sequential cohort, dose-escalation study of BMN 111 in children who are between five and 14 years old. The primary objective is to assess the safety and tolerability of daily subcutaneous doses of BMN 11...